152 related articles for article (PubMed ID: 9548414)
1. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro.
Tosi P; Visani G; Ottaviani E; Testoni N; Pellacani A; Tura S
Eur J Haematol; 1998 Mar; 60(3):161-5. PubMed ID: 9548414
[TBL] [Abstract][Full Text] [Related]
2. No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
Visani G; Isidori A; Grafone T; Tosi P; Santini V; Malagola M; Martinelli G; Piccaluga PP; Gaziev D; Ottaviani E; Sparaventi G; Tura S
Leuk Lymphoma; 2004 Jul; 45(7):1361-4. PubMed ID: 15359633
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Reuter C; Schleyer E; Rolf C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1997 Apr; 11(4):561-71. PubMed ID: 9096697
[TBL] [Abstract][Full Text] [Related]
4. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
[TBL] [Abstract][Full Text] [Related]
5. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.
Seymour JF; Juneja SK; Campbell LJ; Ellims PH; Estey EH; Prince HM
Leukemia; 1999 Nov; 13(11):1735-40. PubMed ID: 10557046
[TBL] [Abstract][Full Text] [Related]
6. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
Braess J; Jahns-Streubel G; Schoch C; Haase D; Haferlach T; Fiegl M; Voss S; Kern W; Schleyer E; Hiddemann W
Br J Haematol; 2001 Jun; 113(4):975-82. PubMed ID: 11442492
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
[TBL] [Abstract][Full Text] [Related]
8. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Marlton P; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich EJ; Estey E
Leukemia; 1995 Jun; 9(6):965-71. PubMed ID: 7596186
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
te Boekhorst PA; Löwenberg B; Sonneveld P
Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
[TBL] [Abstract][Full Text] [Related]
11. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Ghaddar HM; Plunkett W; Kantarjian HM; Pierce S; Freireich EJ; Keating MJ; Estey EH
Leukemia; 1994 Aug; 8(8):1269-74. PubMed ID: 8057660
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
[TBL] [Abstract][Full Text] [Related]
13. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
14. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler HD
Exp Hematol; 1992 Nov; 20(10):1194-200. PubMed ID: 1426099
[TBL] [Abstract][Full Text] [Related]
15. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
16. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
[TBL] [Abstract][Full Text] [Related]
19. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
[TBL] [Abstract][Full Text] [Related]
20. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
Garrido SM; Cooper JJ; Appelbaum FR; Willman CL; Kopecky K; Banker DE
Leuk Res; 2001 Jan; 25(1):23-32. PubMed ID: 11137557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
